Search research articles
Contact Us
Filters
Showing results (1-10 of 99) with videos related to
Page
of 10
Sort By:
Expert Opinion on Biological Therapy
|
January 9, 2003
Alpha-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I
Doug A Brooks
Nature Chemical Biology
|
January 20, 2007
Getting into the fold
Doug A Brooks
Communicative & Integrative Biology
|
July 19, 2012
Innate immunity and exocytosis of antimicrobial peptides
Tetyana Shandala, Doug A Brooks
Trends in Molecular Medicine
|
October 15, 2003
Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder
Doug A Brooks, Revecca Kakavanos, John J Hopwood
Trends in Molecular Medicine
|
June 27, 2006
Stop-codon read-through for patients affected by a lysosomal storage disorder
Doug A Brooks, Viv J Muller, John J Hopwood
Helicobacter
|
March 3, 2009
Monocyte and macrophage killing of helicobacter pylori: relationship to bacterial virulence factors
Glenn N Borlace, Ross N Butler, Doug A Brooks
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
December 15, 2010
Intestinal fructose transport and malabsorption in humans
Hilary F Jones, Ross N Butler, Doug A Brooks
International Journal of Molecular Sciences
|
December 30, 2025
Pathogenesis-Guided Biomarker Assessment: A Shift in Prostate Cancer Diagnostics
Jessica M Logan, Victoria Malone, John J O'Leary, et al.
Molecular Genetics and Metabolism
|
January 20, 2004
Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients
Emma J Parkinson, Viv Muller, John J Hopwood, et al.
Biochimica Et Biophysica Acta
|
October 16, 2003
The alpha-L-iduronidase mutations R89Q and R89W result in an attenuated mucopolysaccharidosis type I clinical presentation
Leanne K Hein, John J Hopwood, Peter R Clements, et al.
Page
of 10
Search research articles
Search
Showing results (1-10 of 99) with videos related to
Sort By:
Page
of 10
Expert Opinion on Biological Therapy
|
January 9, 2003
Alpha-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I
Doug A Brooks
Nature Chemical Biology
|
January 20, 2007
Getting into the fold
Doug A Brooks
Communicative & Integrative Biology
|
July 19, 2012
Innate immunity and exocytosis of antimicrobial peptides
Tetyana Shandala, Doug A Brooks
Trends in Molecular Medicine
|
October 15, 2003
Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder
Doug A Brooks, Revecca Kakavanos, John J Hopwood
Trends in Molecular Medicine
|
June 27, 2006
Stop-codon read-through for patients affected by a lysosomal storage disorder
Doug A Brooks, Viv J Muller, John J Hopwood
Helicobacter
|
March 3, 2009
Monocyte and macrophage killing of helicobacter pylori: relationship to bacterial virulence factors
Glenn N Borlace, Ross N Butler, Doug A Brooks
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
December 15, 2010
Intestinal fructose transport and malabsorption in humans
Hilary F Jones, Ross N Butler, Doug A Brooks
International Journal of Molecular Sciences
|
December 30, 2025
Pathogenesis-Guided Biomarker Assessment: A Shift in Prostate Cancer Diagnostics
Jessica M Logan, Victoria Malone, John J O'Leary, et al.
Molecular Genetics and Metabolism
|
January 20, 2004
Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients
Emma J Parkinson, Viv Muller, John J Hopwood, et al.
Biochimica Et Biophysica Acta
|
October 16, 2003
The alpha-L-iduronidase mutations R89Q and R89W result in an attenuated mucopolysaccharidosis type I clinical presentation
Leanne K Hein, John J Hopwood, Peter R Clements, et al.
Page
of 10